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Supplementary methods 
Study design 
Visit 1 (day 1) occurred within 48 hours of initial presentation to medical care. Patients were then seen for Visits 2 (day 
5±1 day, or exceptionally 2 days), 3 (day 10±1 day, or exceptionally 2 days) and 4 (day 42±2 weeks). At Visit 1 patients 
were instructed on symptom diary card recording and asked to complete the diary at the end of each day for 10 days. 
Symptom diary cards were reviewed at Visit 2 and 3. Convalescent serum was taken at Visit 4 for atypical bacterial 
serology. 
We excluded subjects taking the following list of medications causing prolongation of the QT interval:  
1. Amphetamines 
2. Anti-emetics: Ondansetron, Dolasetron, Granisetron 
3. Opioids: Methadone, Buprenorphine, Oxycodone 
4. Antipsychotics: Droperidol, Thioridazine, Pimozide, Haloperidol, Chlorperazine 
5. Antidepressants: Tricyclic Antidepressants, Trazodone 
6. Antiarrhythmics: Quinidine, Disopyramide, Procainamide, Amiodarone, Sotalol 
7. Antimalarials: Halofantrine 
8. Cisapride 
9. Cocaine 
As there is no list that is regarded as definitive, this list was derived after consulting various different web-based sources 
and was agreed in consultation with all AZALEA PIs. 
Bacteriology/Virology 
We used in house PCR assays of nasal mucus samples, nasal and throat swabs and spontaneous or induced sputum to 
detect picornaviruses (mostly rhinoviruses); respiratory syncytial virus; coronaviruses 229E and OC43; parainfluenza 
viruses 1-3; influenza viruses AH1, AH3, and B; human metapneumoviruses; adenoviruses, bocavirus and the two 
atypical bacteria Mycoplasma (M.) pneumoniae and Chlamydophila (C.) pneumoniae, as described1. In addition we also 
used commercial MutaPLATE® real time (TaqMan) PCR kits for detection of C. pneumoniae and M. pneumoniae 
(Immundiagnostik, Bensheim, Germany) according to the manufacturer’s instructions. 
Serology for IgM for M. pneumoniae and C. pneumoniae, was performed on acute serum samples taken at exacerbation 
and for IgA and IgG for M. pneumoniae and C. pneumoniae, on acute serum samples taken at exacerbation and 
convalescent samples taken at Visit 4 using MEDAC M. pneumoniae and C. pneumoniae IgM, IgA and IgG ELISAs 
(Medac, Hamburg, Germany) according to the manufacturer’s instructions. 
All the above assays were performed centrally at Prof Johnston’s laboratory at Imperial College London. 
Standard sputum quantitative bacterial cultures were performed locally at each site using local Microbiology Laboratory 
standard operating procedures. 
 
Statistical analyses 
Sample Size 
The sample size calculations were based on the primary outcome: the telithromycin study2 found a mean difference in 
symptom score of -0.3 (standard deviation [SD] 0.783) between active and placebo groups at 10 days. Using a two-sided 
t-test at 1% significance level, with 80% power, 161 patients in each group were needed to detect the same difference in 
asthma scores between the groups. The significance level of 1% in the above calculation was chosen to provide greater 
certainty in assessment of the primary outcome variable and to provide greater power for the subgroup analyses. 
Assuming a drop-out rate of 15%2, we proposed to recruit 190 patients to each arm.  
Randomization was via a secure server performed using the InForm ITM (Integrated Trial Management) System. 
Patient allocation was stratiﬁed by center in random length blocks. The randomization lists were generated by an 
Imperial Clinical Trials Unit (ICTU) statistician. Details such as block size were kept conﬁdential. There was no 
requirement for unblinding during the AZALEA trial therefore no patients were unblinded before statistical analysis. 
 
Multilevel modeling: the three main components of the model 
Let DSid represent the diary score for patient i on day d, d = 1, …, 10, and t(i) represent the treatment given to individual i 
(azithromycin or placebo). Then model DSid as the sum of three components: an intercept term, a change over time term 
and a residual error term, i.e. 
𝐷𝑆𝑖𝑑 = 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡𝑖 + 𝑐ℎ𝑎𝑛𝑔𝑒 𝑜𝑣𝑒𝑟 𝑡𝑖𝑚𝑒𝑡(𝑖)𝑑 + 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝑒𝑟𝑟𝑜𝑟𝑖𝑑  
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Possible choices for each of these components are outlined below. The options explored for the primary analysis were 
determined by the results of the exploratory analysis, and the final choice will be the simplest model that satisfies 
standard checks of model fit (e.g. residual plots). 
 
Intercept term 
 
The intercept term will estimate the diary score on day 1 (the day of randomization and start of the study medication). 
This term will comprise an individual level random eﬀect, which will be drawn from a distribution parameterized using 
the associated center level random eﬀect. Hence the unexplained variation in the diary scores will be split into three 
components corresponding to the three levels of the model, i.e. the variation attributable to the center (between center 
variation) and the individual (between individual variation), as well as the residual variation (within individual variation). 
 
Additionally, baseline covariates can be incorporated into the model at the individual level. None will be incorporated for 
the initial analysis unless the baseline characteristics analysis reveals a substantial imbalance. Further analyses will 
examine the eﬀect of incorporating baseline variables (age, gender, asthma severity, smoking history and asthma 
exacerbation). 
 
Change over time (cot) term 
 
This term will capture the change in the diary score from the start of the study medication (day 1), hence time will enter 
the model as day 1. The simplest assumption would be a linear change over the period, however alternatives may need to 
be considered as the rate of change may not be constant over the 10 day period. Alternatives are to include a quadratic 
term or use splines. The coeﬃcients in this term will be dependent upon treatment. 
 
Residual error term 
 
We were assuming that the residual errors have a Normal distribution. An alternative was to assume that these errors 
follow a heavier tailed distribution such as a t distribution with 4 degree of freedom, which will provide robustness to 
outliers. Normality of residual error was checked graphically. 
Missing data 
Before starting data analysis, the level and pattern of the missing data in the baseline variables and outcomes was 
analyzed by forming appropriate tables. Additionally, the likely causes of any omissions were investigated. This 
information was used to determine whether the level and type of missing data had the potential to introduce bias into the 
analysis or to substantially reduce the precision of estimates related to treatment eﬀects. Missing data in the patient diary 
took one of several forms: no patient diary returned for any day (patient omissions), all data missing for one or more days 
(day omissions) and data missing for some but not all the individual questions for a particular day (item omissions). Of 
these, the level of item omissions was expected to be minimal. According to the SAP if any item omissions occurred in 
diary scores, the scores for the missing questions were interpolated from the previous and subsequent day scores. This 
process was conducted for 2 missing entries. 
If any item omissions occurred in AQLQ scores the summary score for that day was treated as missing.  
Missing data for the pulmonary function tests were expected to be due to the spirometer not recording some measures. As 
this was unrelated to the patient outcome, it was reasonable to assume that these omissions were uninformative and that 
multi-level models fitted to all observed data would provide unbiased parameter estimates. 
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Supplementary results 
Of the 199 patients randomized, 193 (97%) were from secondary care hospitals and 6 (3%) from the primary care center. 
Exploratory analysis of the primary outcome  
As a check for outliers and imbalances, a series of longitudinal plots (one for each center) of diary score for each patient, 
diﬀerentiating between treatment arm were produced (see Supplementary eFigure 1). Boxplots of diary scores by 
treatment arm for each day were produced to show the distribution of the observed scores graphically in Supplementary 
eFigure 2. Supplementary eTable 1 shows the observed mean diary scores and standard deviations for each treatment 
arm by day and the number of observations. Additionally, a table of summary statistics of the diary scores by day and 
treatment arm was produced, including the number of observations, mean, standard deviation, median, lower and upper 
quartiles (Supplementary eTable 2). 
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Supplementary eFigure 1: Observed diary scores for each center by treatment arm
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Supplementary eFigure 2: Boxplots of observed symptom diary scores 
 
 
Supplementary eTable 1: Observed mean symptom scores for each day by treatment 
group and their standard deviation 
 
day 
1 
day 
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
Placebo 
(SD) 
4.18 
(1.48) 
3.45 
(1.62) 
3.12 
(1.47) 
3.04 
(1.57) 
2.87 
(1.58) 
2.79 
(1.56) 
2.80 
(1.69) 
2.43 
(1.53) 
2.32 
(1.55) 
2.20  
(1.51) 
N 77 86 85 81 81 80 79 77 74 68 
Active 
(SD) 
4.14 
(1.38) 
3.51 
(1.42) 
3.09 
(1.45) 
2.78 
(1.58) 
2.63 
(1.51) 
2.44 
(1.54) 
2.19 
(1.53) 
2.24 
(1.61) 
2.22 
(1.71) 
2.09  
(1.71) 
N 71 85 86 84 80 78 81 80 78 71 
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Supplementary eTable 2: Detailed statistics of observed diary scores 
Placebo Active  
N Diary 
score, 
mean (SD) 
Diary 
score, 
median 
(IQR) 
 
N Diary 
score, 
mean (SD) 
Diary score, 
median (IQR) 
day 1 
77 4.18 (1.48) 4.25 
(3.00, 5.50) 
day 1 
71 4.14 (1.38) 4.25 
(3.25, 5.00) 
day 2 
86 3.45 (1.62) 3.50 
(2.25, 5.00) 
day 2 
85 3.51 (1.42) 3.75 
(2.50, 4.75) 
day 3 
85 3.12 (1.47) 3.00 
(2.00, 4.25) 
day 3 
86 3.09 (1.45) 3.00 
(2.00, 4.25) 
day 4 
81 3.04 (1.57) 3.25 
(1.75, 4.25) 
day 4 
84 2.78 (1.58) 2.50 
(1.50, 4.00) 
day 5 
81 2.87 (1.58) 3.00 
(1.50, 4.25) 
day 5 
80 2.63 (1.51) 2.50 
(1.38, 3.75) 
day 6 
80 2.79 (1.56) 2.63 
(1.50, 4.00) 
day 6 
78 2.44 (1.54) 2.25 
(1.25, 3.75) 
day 7 
79 2.80 (1.69) 3.00 
(1.25, 4.00) 
day 7 
81 2.19 (1.53) 2.25 
(1.00, 3.25) 
day 8 
77 2.43 (1.53) 2.50 
(1.00, 3.50) 
day 8 
80 2.24 (1.61) 2.00 
(1.00, 3.50) 
day 9 
74 2.32 (1.55) 2.38 
(1.00, 3.25) 
day 9 
78 2.22 (1.71) 2.00 
(0.75, 3.25) 
day 10 
68 2.20 (1.51) 2.25 
(0.88, 3.25) 
day 10 
71 2.09 (1.71) 1.75 
(0.50, 3.50) 
 
A linear change was assumed in the model for the diary score over time with different slopes for the two treatment arms. 
Additionally, equal mean scores were assumed at baseline for the two groups as any inequality could only have occurred 
by chance, due to randomization. In order to reduce bias caused by the observed difference at baseline, the main effect of 
the interaction term was not included in the model as an independent covariate. Sensitivity analysis with the inclusion of 
this covariate was conducted. The estimated mean diary score at baseline (day 1) in the whole study population was 3.66 
(95% CI: 3.41; 3.90). In addition to the decrease observed in the placebo group, the decrease of the diary score in the 
azithromycin group was slightly greater. On average the difference in change compared to the placebo group was -0.018 
per day (95% CI: -0.074 , 0.037). The estimated differences with their 95% confidence intervals for each day can be 
found in Supplementary eTable 3. The mean “natural” background daily decrease (decrease in placebo group) in diary 
score was -0.18 (95% CI for the first day alone: -0.22; 0.14). On day 10, the difference between the two groups was not 
statistically significant. The estimated mean diary score was lower in the azithromycin group by -0.166 (95% CI: -0.670; 
0.337). On Day 5 the difference was -0.074 (95% CI: -0.298; 0.150) between the two groups. 
 
Supplementary eTable 3: Estimated difference in change of diary scores from 
baseline and 95% confidence intervals for azithromycin compared to the placebo  
 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
7 
Day 
8 
Day 
9 
Day 
10 
Difference 
in Change 
from 
baseline 
0 
-
0.018 
-
0.037 
-
0.055 
-
0.074 
-
0.092 
-
0.111 
-
0.129 
-
0.148 
-
0.166 
95% 
Confidence 
Interval  
- 
- 
-
0.074 
0.037 
-
0.149 
0.075 
-
0.223 
0.112 
-
0.298 
0.150 
-
0.372 
0.187 
-
0.446 
0.224 
-
0.521 
0.262 
-
0.595 
0.299 
-
0.670 
0.337 
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Model selection 
 
Different relationships between time and diary scores were compared including linear, quadratic and square root 
relationships. These models differed in their ”time” covariate. Fixed and random effects and the use of splines were also 
investigated. The plots of level 1 and level 2 residuals (where appropriate) were assessed for these models, including the 
model with splines at day 3 and day 7 and the fitted and observed values were also investigated graphically. As it can be 
seen (Supplementary eFigure 3), the more complex alternative models gave more flexibility than the standard linear 
model, but overall the residuals were just barely lower and the pattern of residuals remain the same, so in order of 
simplicity a linear model was chosen to calculate the estimated scores. 
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Supplementary eFigure 3: Boxplot of residuals for linear and quadratic models 
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Details of the models for diary and AQLQ Scores 
Supplementary eTable 4: Diary score 
Fixed-effects Parameters 
Covariates  Coefficient 95% CI P value 
Constant Mean score at baseline in the 
Placebo group 
3.6595 3.4169       3.9022 0.000 
Days (centered) Daily change in Placebo group -0.1792 -0.2217     -0.1367 0.000 
Treatment #Day 
(interaction) 
(Treatment effect) 
Difference in daily change 
compared to the Placebo group  
-0.0185 
 
-0.0744      0.0374 0.517 
Random-effects Parameters 
Level variance Estimate 95% CI* 
Site Constant (intercept) 0.0412 0.0012      1.4372 
Subject Constant (intercept) 
Days (slope) 
1.6863 
0.0334 
1.3063      2.1769 
0.0251      0.0443 
 Covariance Days - Constant -0.0957 -0.1461     -0.0453 
 residuals 0.6941 0.6415      0.7510 
*95% confidence intervals presented for the variance parameters should not be used to test the significance of the variance parameters 
as the lower limits of these intervals can never be smaller than zero since variances are strictly positive quantities 
 
LR test vs. linear regression: p < 0.0001 
 
Supplementary eTable 5: Acute AQLQ 
Fixed-effects Parameters 
Covariates  Coefficient 95% CI P value 
Constant Mean score at baseline in the 
Placebo group 
4.727 4.491       4.962 0.000 
Visits (centered) Per visit change in Placebo group 0.429 0.275       0.583 0.000 
Treatment #Visit 
(interaction) 
(Treatment effect) 
 
0.065 -0.138       0.269 0.530 
Random-effects Parameters 
Level variance Estimate 95% CI* 
Site Constant (intercept) 0.063 0.009       0.450 
Subject Constant (intercept) 
Visits (slope) 
0.888 
0.165 
0.583       1.353 
0.059       0.464 
 Covariance Visits - Constant -0.074 -0.272       0.125 
 residuals 0.903 0.727       1.123 
*95% confidence intervals presented for the variance parameters should not be used to test the significance of the variance parameters 
as the lower limits of these intervals can never be smaller than zero since variances are strictly positive quantities 
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Supplementary eTable 6: Mini AQLQ 
Fixed-effects Parameters 
Covariates  Coefficient 95% CI P value 
Constant Mean score at baseline in the 
Placebo group 
3.355 3.196       3.514 0.000 
Visits (centered) Per visit change in Placebo group 0.350 0.214       0.486 0.000 
Treatment #Visit 
(interaction) 
(Treatment effect) 
 
-0.021 -0.204       0.163 0.823 
Random-effects Parameters 
Level variance Estimate 95% CI* 
Site Constant (intercept) 0.000 0.000       0.000 
Subject Constant (intercept) 
Visits (slope) 
0.803 
0.185 
0.569       1.133 
0.097       0.350 
 Covariance Visits - Constant -0.076 -0.220       0.069 
 residuals 0.566 0.457       0.703 
*95% confidence intervals presented for the variance parameters should not be used to test the significance of the variance parameters 
as the lower limits of these intervals can never be smaller than zero since variances are strictly positive quantities 
 
Secondary outcome analysis 
For all secondary outcomes, an exploratory analysis and assessment of missing data was completed prior to the main 
analysis. This was analogous to that outlined for the primary outcome. Multilevel models, similar to those specified for 
the primary outcome, were used to analyze the acute asthma and mini-asthma questionnaires and also for the pulmonary 
function tests. Details of the models used for AQLQ and mini AQLQ respectively can be found in Supplementary 
eTables 5 and 6.  
 
Acute AQLQ and mini AQLQ analysis  
Boxplots of acute AQLQ by treatment arm for each visit are shown in Supplementary eFigure 4.  
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Supplementary eFigure 4: Boxplots of observed acute AQLQ scores 
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Supplementary eTable 7 shows the observed mean and standard deviation of Acute AQLQ scores for each treatment 
arm by visit and the number of observations. 
Supplementary eTable 7: Detailed statistics of observed acute AQLQ scores 
Placebo 
 Acute AQLQ 
Visit N Mean Sd Median P25 P75 
1 100 4.8 1.3 5.0 4.0 5.6 
2 87 5.3 1.4 5.7 4.2 6.4 
3 83 5.6 1.5 6.1 4.8 6.7 
Active 
 Acute AQLQ 
Visit N Mean Sd Median P25 P75 
1 96 4.6 1.4 4.6 3.6 5.8 
2 84 5.4 1.3 5.7 4.6 6.6 
3 80 5.6 1.5 6.1 4.9 6.8 
 
As for the primary outcome, multilevel modeling was carried out assuming equal mean scores at baseline and linear 
change for the acute AQLQ and mini-AQLQ scores over time with different slopes for the two treatment arms. 
Differences in the change of acute AQLQ scores for each visit with the 95% confidence intervals can be found in 
Supplementary eTable 8. At visit 3 (day 10) there was no statistically significant difference between the two groups. 
According to the model, at visit 3, there was 0.130 (95% CI: -0.276; 0.539) greater acute AQLQ score estimated in the 
azithromycin group than the placebo group.  
 
Supplementary eTable 8: Estimated difference in acute AQLQ score by visits 
Acute AQLQ score 
Visit 1 
(Day 1) 
Visit 2 
(Day 5) 
Visit 3 
(Day 10) 
Difference in change 
compared to Placebo 
group 
0 0.065 0.130 
95% Confidence 
Interval 
- -0.138; 0.269 -0.276; 0.539 
 
The same analyses were conducted for mini AQLQ scores as for acute AQLQ scores. Boxplots of Mini-AQLQ, by 
treatment arm, for each visit, are shown in Supplementary eFigure 5. Supplementary eTable 9 shows the observed 
mean and standard deviation of mini AQLQ scores for each treatment arm by visit. 
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Supplementary eFigure 5: Boxplots of observed mini AQLQ scores 
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Supplementary eTable 9: Detailed statistics of observed mini AQLQ scores 
Placebo 
 Mini AQLQ 
Visit Mean Sd Median P25 P75 
1 3.4 1.1 3.2 2.6 4.0 
2 3.6 1.2 3.4 2.7 4.3 
3 4.1 1.3 3.9 3.1 4.9 
Azithromycin 
 Mini AQLQ 
Visit Mean Sd Median P25 P75 
1 3.4 1.2 3.1 2.5 4.2 
2 3.6 1.1 3.6 2.9 4.3 
3 4.1 1.3 4.1 3.1 5.1 
 
Differences in the change of mini AQLQ scores for each visit with 95% confidence intervals are shown in 
Supplementary eTable 10. At visit 3 (day 10) there was no statistically significant difference between the two groups. 
According to the model, at visit 3 there was -0.042 (95% CI: -0.409; 0.325) lower mini AQLQ score estimated in the 
azithromycin group than the placebo group.. 
 
Supplementary eTable 10: Estimated difference in mini AQLQ score azithromycin 
compared to placebo by visits 
Mini AQLQ Visit 1 
(Day 1) 
Visit 2 
(Day 5) 
Visit 3 
(Day 10) 
Difference in change 
compared to Placebo 
group 
0 -0.020 -0.042 
95% Confidence 
interval 
- -0.204; 0.163 -0.409; 0.325 
 
Pulmonary function test analysis  
For the pulmonary function tests similar exploratory analyses and multilevel modelling was conducted as for AQLQ 
scores. Supplementary eTable 11 shows the observed pulmonary function test values (mean and standard error) for each 
visit by treatment arm.  
Supplementary eTable 12 shows the estimated differences in change for azithromycin compared to placebo group with 
95% confidence intervals by visit for each pulmonary function test. 
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Supplementary eTable 11: Observed mean (SD) pulmonary function test results by 
visit and treatment arm 
Active Group  Placebo group 
Visit 1 
Day 1 
Visit 2 
Day 5 
Visit 3 
Day 10 
 Visit 1 
Day 1 
Visit 2 
Day 5 
Visit 3 
Day 10 
97 85 80 N 101 90 83 
1.94 
(0.74) 
2.23 
(0.77) 
2.30 
(0.83) 
FEV1(liters), mean (SD) 2.11 
(0.79) 
2.34 
(0.83) 
2.38 
(0.91) 
2.80 
(1.03) 
3.13 
(1.00) 
3.25 
(1.08) 
FVC(liters), mean (SD) 3.09 
(1.05) 
3.40 
(1.10) 
3.38 
(1.09) 
69.66 
(13.33) 
71.71 
(12.02) 
71.00 
(12.38) 
FEV1/FVC ratio, mean 
(SD) 
68.83 
(13.71) 
69.28 
(12.24) 
70.02 
(12.71) 
1.59 
(0.89) 
1.85 
(0.94) 
1.77 
(0.92) 
FEF25-75%(liters/sec), 
mean (SD) 
1.74 
(1.14) 
1.83 
(1.08) 
1.94 
(1.20) 
1.92 
(1.06) 
2.12 
(1.05) 
2.19 
(1.08) 
FEF50%(liters/sec), 
mean (SD) 
2.04 
(1.26) 
2.15 
(1.24) 
2.32 
(1.35) 
288.0 
(107.5) 
345.0 
(109.0) 
363.3 
(108.4) 
PEF(liters/min), mean 
(SD) 
320.2 
(102.6) 
349.5 
(110.1) 
356.8 
(118.1) 
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Supplementary eTable 12: Estimates of pulmonary function mean differences and 
95% CI in brackets 
 Difference in 
change compared 
to Placebo at visit 3 
(Day 10) 
Difference in 
change  
compared to 
Placebo at visit 2 
(Day 5) 
Per visit 
change in 
Placebo 
Baseline 
mean 
FEV1(liters) 0.050  
(-0.132; 0.231) 
0.024  
(-0.067; 0.116) 
0.164  
(0.099; 0.228) 
2.011  
(1.875; 2.146) 
FVC(liters) 0.038  
(-0.166; 0.243) 
0.019  
(-0.083; 0.122) 
0.200  
(0.127; 0.272) 
2.959  
(2.809; 3.110) 
FEV1/FVC ratio 1.379  
(-1.559; 4.316) 
0.689  
(-0.779; 2.158) 
0.365 (-0.732; 
1.463) 
69.5  
(67.7; 71.4) 
FEF25-75%(liters/sec) 0.036  
(-0.192; 0.265) 
0.018  
(-0.096; 0.132) 
0.116  
(0.035; 0.197) 
1.631  
(1.470; 1.792) 
FEF50%(liters/sec) 0.045  
(-0.234; 0.324) 
0.022  
(-0.117; 0.162) 
0.161  
(0.062; 0.260) 
1.931  
(1.750; 2.112) 
PEF(liters/min) 18.03  
(-8.56; 44.62) 
9.016  
(-4.278; 22.31) 
24.66  
(15.01; 34.31) 
296.3  
(272.0; 321.6) 
 
Subgroup studies 
The same model as outlined for the primary outcome was used for subgroup analyses which including the following:  
 
 Bacteria culture positive or negative in sputum: Supplementary eTable 13 
 Viral tests positive or negative in nasal mucus, nasal swab, throat swab or sputum: Supplementary 
eTable 14 
 Atypical bacteria positive or negative in nasal mucus, nasal swab, throat swab, sputum or serological 
testing: Supplementary eTable 15 
 
Sputum bacterial culture was positive in 6% of subjects (4.1% active, 7.8% placebo). Nasal/throat swab/mucus and/or 
sputum atypical bacterial PCR and/or atypical bacterial serology were positive in 4.5% of patients (5.2% active, 3.9% 
placebo). Overall a bacteria/atypical bacterial test positive occurred in 10.6% of patients (9.3% active, 11.8% placebo). 
Nasal/throat swab/mucus and/or sputum virus PCR were positive in 18.1% of patients (16.5% active, 19.6% placebo). 
 
Supplementary eTable 13: Estimated Day 10 difference in change of diary scores 
from baseline with 95% confidence intervals with azithromycin compared to the 
placebo group in sputum culture bacteria positive or negative subgroup 
Group Whole study 
population 
(N=176) 
Sputum bacterial 
culture missing 
(N=93) 
Sputum bacterial 
culture positive 
(N= 12) 
Sputum bacterial 
culture negative 
(N= 71) 
Day 10 
difference in 
change 
-0.166 -0.114 1.178 -0.410 
95% CI -0.670; 0.337 -0.821; 0.594 -0.497; 2.853 -1.183; 0.364 
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Supplementary eTable 14: Estimated Day 10 difference in change of diary scores 
from baseline with 95% confidence intervals for azithromycin compared to placebo in 
virus PCR test positive or negative subgroups 
Group Whole study 
population 
(N=176) 
Virus PCR positive 
(N=31) 
Virus PCR negative 
(N= 138) 
Day 10 difference in 
change 
-0.166 -0.100 -0.106 
95% CI -0.670; 0.337 -1.170; 0.969 -0.683; 0.472 
 
Supplementary eTable 15: Estimated Day 10 difference in change of diary scores 
from baseline with 95% confidence intervals for azithromycin compared to the 
placebo group in atypical bacteria and any bacteria positive or negative subgroups 
Group Whole study 
population 
(N=176) 
Atypical* bacteria 
positive (N=8†) 
Atypical* bacteria 
negative (N=157) 
Any bacterial test 
positive (N=20) 
Day 10 
difference in 
change 
-0.166 1.391 0.044 0.198 
95% CI -0.670; 0.337 -1.214; 3.996 -0.465; 0.554 -1.546; 1.942 
* C. pneumoniae or M. pneumoniae 
†There were 9 patients with positive atypical bacteriology test results, but one of them had no diary score records 
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Supplementary eFigure 6: Observed mean diary scores and standard errors of the 
any bacterial test positive subgroup (N=20) by treatment arm 
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Supplementary eFigure 7: Observed mean diary scores and standard errors of the 
atypical bacterial test positive subgroup (N=8) by treatment arm 
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Supplementary eFigure 8: Observed mean diary scores and standard errors of the 
Bacteria culture positive in sputum subgroup (N=12) by treatment arm 
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Subgroup analysis based on time to receipt of study drug 
A subgroup analysis on those who received study drug within 24hrs of initial presentation to medical care (N=104, 52 
azithromycin, 52 placebo, difference at day 10 0.001 (95% CI: -0.634 to 0.636) and those who received study drug 24hrs 
or more after initial presentation (N=72, 35 azithromycin, 37 placebo, difference at day 10 -0.356 (95% CI: -1.128 to - 
0.417) suggested there was no evidence that benefit may have been greater in those that received study drug earlier. 
 
Post Hoc analysis 
The AZISAST study reported that azithromycin prophylaxis reduced exacerbations in subjects with non-eosinophilic 
severe asthma (blood eosinophilia ≤200/µL): 0.44 (95% CI 0.25 to 0.78) versus 1.03 (95% CI 0.72 to 1.48) (P=0.013)3. 
We therefore carried out a similar post hoc analysis. There were 166 patients with blood eosinophil results and diary 
score records. Multilevel modeling of our primary outcome revealed no significant benefit in those with blood 
eosinophils <200/µL (N=103: difference -0.265; 95% CI -0.873 to 0.363) or <300/µL (N=118: difference: -0.180; 95% 
CI -0.791 to 0.432). 
 
Safety data analysis 
Protocol reporting of adverse events were from the time the patient gave informed consent until seven days after the last 
dose of study medication. Using the information recorded on the adverse event eCRF, each adverse event was 
categorized using MedDRA coding System Organ Class (SOC) terms by a designee of the Chief Investigator. The 
number of adverse events and patients affected in each category by treatment arm can be found in Supplementary 
eTable 16 and Supplementary eTable 17.  
 
Supplementary eTable 1: Number of adverse events by SOC category and treatment 
arm 
 Arm  
Adverse Event Category* Active Placebo Total 
 No. No. No. 
Cardiac disorders 4 2 6 
Eye disorders 2 1 3 
Gastrointestinal disorders 35 24 59 
General disorders 18 25 43 
Infections and infestations 0 1 1 
Musculoskeletal and connective tissue 
disorders 4 6 10 
Nervous system disorders 15 14 29 
Psychiatric disorders 1 2 3 
Reproductive system and breast disorders 0 1 1 
Respiratory, thoracic and mediastinal 
disorders 27 37 64 
Skin and subcutaneous disorders 0 1 1 
Total 106 114 220 
*as advised by Chief Investigator or designee, based on description 
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Supplementary eTable 17: Number of patients affected by SOC category (a patient is 
only shown once in each category) 
 Arm  
Adverse Event Category* Active Placebo Total 
 No. No. No. 
Cardiac disorders 4 2 6 
Eye disorders 2 1 3 
Gastrointestinal disorders 25 20 45 
General disorders 16 19 35 
Infections and infestations 0 1 1 
Musculoskeletal and connective tissue 
disorders 3 4 7 
Nervous system disorders 14 13 27 
Psychiatric disorders 1 2 3 
Reproductive system and breast disorders 0 1 1 
Respiratory, thoracic and mediastinal disorders 20 28 48 
Skin and subcutaneous disorders 0 1 1 
Total† (number of patients affected) 85(51) 92 (52) 177 (103) 
*as advised by Chief Investigator or designee, based on description 
†a patient may have more than one adverse event in any category 
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Supplementary eTable 18 shows the number of adverse events by category and relationship to study medication.  The 
relationship is missing for four adverse events, and these are shown as “Unknown”. No adverse events were deﬁnitely 
related to the study medication. 
 
Supplementary eTable 18: Number of Adverse Events by SOC category and 
Relationship to Study Medication 
 
Relationship to study Medication 
Adverse Event Category* Not 
related 
Unlikely Possibl
e 
Probable Unknown Total 
 No. No. No. No. No. No. 
Cardiac disorders 3 2 1 0 0 6 
Eye disorders 1 2 0 0 0 3 
Gastrointestinal disorders 9 5 36 7 2 59 
General disorders 20 11 11 0 1 43 
Infections and infestations 1 0 0 0 0 1 
Musculoskeletal and 
connective 
 tissue disorders 6 3 1 0 0 10 
Nervous system disorders 8 13 8 0 0 29 
Psychiatric disorders 0 3 0 0 0 3 
Reproductive system and  
breast disorders 1 0 0 0 0 1 
Respiratory, thoracic and  
mediastinal disorders 49 14 0 0 1 64 
Skin and subcutaneous 
disorders 0 0 1 0 0 1 
Total 98 53 58 7 4 220 
*as advised by Chief Investigator or designee, based on description 
 
Multiple adverse events were reported for some patients, with 51 patients (just less than half of those with adverse 
events) reporting more than one. Ten adverse events were reported for one subject. Supplementary eTable 19 provides 
further detail about the distribution of the 220 adverse events between the 103 patients who reported adverse events. 
 
Supplementary eTable 19: Number of Adverse Events Reported for Individual 
patients 
 Treatment Arm  
Number of Adverse 
Events 
Active Placebo Total 
 No. No. No. 
1 24 28 52 
2 12 9 21 
3 7 6 13 
4 4 4 8 
5 3 2 5 
6 1 1 2 
8 0 1 1 
10 0 1 1 
Total 51 52 103 
 
Details of the adverse events classiﬁed as cardiac disorders are given in Supplementary eTable 20. None of these were 
classiﬁed as a serious adverse event. 
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Supplementary eTable 20: Listing of adverse events classiﬁed as Cardiac Disorders 
Age  
(years
) 
Arm Description Site* Relation Severity Outcome Action
† 
Duration 
26 PLACEBO chest pain NOC Not 
related 
Moderate Recovered None Intermittent 
36 ACTIVE chest pain NOC Not 
related 
Mild Not yet 
recovered 
None Continuous 
22 ACTIVE palpitations POR Unlikely Mild Recovered None Intermittent 
38 ACTIVE chest pain and pain  
under left arm pit 
POR Unlikely Mild Recovered None Single Episode 
55 ACTIVE chest pain POR Not 
related 
Mild Recovered None Single Episode 
42 PLACEBO feeling of tachycardia SMH Possible Mild Recovered None Single Episode 
*NOC  = Nottingham City  Hospital; POR  = Portsmouth Hospitals NHS Trust; SMH = St Mary’s Hospital, Imperial College Healthcare NHS Trust 
†Action taken concerning study medication 
 
Details of the serious adverse events are given in Supplementary eTables 21 and 22. There were 3 in the placebo group and one in the azithromycin group. All were related to the 
asthma exacerbations being studied and were considered unlikely or not related to study drug. 
 
Supplementary eTable 21: Serious Adverse Events 
 
Age  
(years) 
Arm Classification 
Action  
taken 
Event Description Site 
Relation to  
study drug 
Severity 
18 PLACEBO Serious 
Hospitalisation 
required 
Pt became wheezy and short of breath, 13/10/12, 
presented to accident and emergency on  
14/10/2012 and was admitted overnight.  
Diagnosis exacerbation of asthma.  
GLA Unlikely Moderate 
22  PLACEBO Serious 
Hospitalisation  
required 
Exacerbation of underlying asthma. Admitted 
 to Hospital at 9am on 7/Oct/2013 with extreme  
symptoms of breathlessness.   
NNU Not related Severe 
47 PLACEBO Serious 
Hospitalisation  
required 
Acute exacerbation of asthma A32 Not related Moderate 
49. ACTIVE Serious 
Hospitalisation  
required 
Shortness of breath and wheeze- non- infective  
exacerbation of asthma 
A29 Not related Moderate 
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Supplementary eTable 22: Serious Adverse Events continued 
Frequency Comments Ongoing Outcome Category 
Single 
Episode 
 No  
Recovered Respiratory, 
thoracic and 
mediastinal 
disorders 
Unknown 
Continuation of 
patients existing 
underlying 
condition. Classed 
as AE 
No  Recovered 
Respiratory, 
thoracic and 
mediastinal 
disorders 
Single 
Episode 
Admitted to hospital 
in Chester with 
asthma 
exacerbation for 3 
nights. 
No  Recovered 
Respiratory, 
thoracic and 
mediastinal 
disorders 
Single 
Episode 
 
Patient was 
admitted with 
shortness of breath 
and kept in 
overnight 
Yes 
Not yet 
recovered 
Respiratory, 
thoracic and 
mediastinal 
disorders 
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Data Monitoring and Ethics Committee 
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Trial Steering Committee 
A Trial Steering Committee (TSC) was established to oversee the conduct of the study. The TSC membership is listed below:  
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